Effect of vitamin D₃ on the osteogenic differentiation of human periodontal ligament stromal cells under inflammatory conditions

Alice Blufstein¹ | Christian Behm¹,² | Barbara Kubin¹ | Johannes Gahn¹ | Xiaohui Rausch-Fan¹ | Andreas Moritz¹ | Oleh Andrukhov¹

Abstract

Objectives: Vitamin D₃ is known to activate osteogenic differentiation of human periodontal ligament stromal cells (hPDLSCs). Recently, inflammatory stimuli were shown to inhibit the transcriptional activity of hPDLSCs, but their effect on vitamin D₃-induced osteogenic differentiation is not known. The present study aimed to investigate whether the effects of 1,25-dihydroxyvitamin D₃ (1,25(OH)₂D₃) and 25-hydroxyvitamin D₃ (25(OH)D₃) on the osteogenic differentiation of hPDLSCs are also altered under inflammatory conditions. Furthermore, the expression of osteogenesis-related factors by hPDLSCs under osteogenic conditions was assessed in the presence of inflammatory stimuli.

Materials and Methods: Primary hPDLSCs of six donors were cultured in osteogenic induction medium containing either 1,25(OH)₂D₃ (0-10 nM) or 25(OH)D₃ (0-100 nM) in the presence and absence of Porphyromonas gingivalis lipopolysaccharide (LPS) or Pam3CSK4 for 7, 14 and 21 days. Osteogenic differentiation of hPDLSCs was evaluated by analysis of mineralization as assessed by Alizarin Red S staining and gene expression levels of osteogenesis-related factors osteocalcin, osteopontin and runt-related transcription factor 2 (RUNX2) were analysed with qPCR.

Results: Treatment with 1,25(OH)₂D₃ significantly enhanced the osteogenic differentiation of hPDLSCs and their expression of osteocalcin and osteopontin. The 1,25(OH)₂D₃-triggered expression of osteogenesis-related factors was significantly lower in the presence of Pam3CSK4, but not P. gingivalis LPS. None of the inflammatory stimuli had significant effects on the 1,25(OH)₂D₃-induced osteogenic differentiation. 25(OH)D₃ neither affected gene expression levels nor osteogenic differentiation of hPDLSCs cultured in osteogenic induction medium.

Conclusion: The results of this study indicate that inflammatory stimuli also diminish the 1,25(OH)₂D₃-induced expression of osteogenesis-related factors in hPDLSCs under osteogenic conditions, while having no effect on the osteogenic differentiation.

Keywords: mesenchymal stromal cells, osteogenesis, periodontal ligament, vitamin D
1 | INTRODUCTION

Vitamin D₃ is a fat-soluble steroid hormone that plays a pivotal role in numerous physiological functions, particularly bone metabolism. Although it can be obtained from several nutritional sources, humans are largely dependent on vitamin D₃ production in the skin. Upon exposure to ultraviolet B radiation, 7-dehydrocholesterol in the epidermis is photolysed to previtamin D₃ and further converted to vitamin D₃. This biologically inactive form is hydroxylated via the 25-hydroxylase into the most abundant circulating vitamin D₃ metabolite 25-hydroxyvitamin D₃ (25(OH)D₃). The conversion into the biologically most active form 1,25-dihydroxyvitamin D₃ (1,25(OH)₂D₃) is facilitated via 1α-hydroxylation. This process occurs predominantly in the kidneys, but can also be observed in extrarenal tissues, such as the periodontium. 1,25(OH)₂D₃ exerts its numerous functions via binding to vitamin D receptor (VDR), which is expressed in almost all cells. Apart from its role in bone metabolism, the active vitamin D₃ metabolite possesses strong immunomodulatory, anti-inflammatory and anti-proliferative properties.

Vitamin D₃ has versatile effects in periodontal ligament stromal cells (hPDLSCs). hPDLSCs fulfill the minimal criteria of mesenchymal stromal cells and play a crucial role in periodontal tissue homeostasis. 1,25(OH)₂D₃ has been observed to enhance the osteogenic differentiation of hPDLSCs, to increase their expression of osteogenesis-related factors and to dampen their inflammatory response.

Considering these numerous positive effects, vitamin D₃ deficiency is unsurprisingly associated with an increased risk of periodontal disease. Periodontitis is a multifactorial chronic disease leading to destruction of all periodontal tissues, namely gingiva, alveolar bone, cementum and periodontal ligament. It is initiated by a shift of a symbiotic to a dysbiotic oral microbiota and is driven by an excessive inflammatory response.

As summarized in our previous study, there are several reports about the influence of vitamin D₃ supplementation during periodontitis treatment. Surprisingly, supplementation of vitamin D₃ has never been shown to be beneficial during non-surgical periodontal treatment so far. Our previous study focussed on finding a possible explanation for this. As inflammation is still strongly pronounced during the initial phase of periodontitis therapy, we investigated the effects of vitamin D₃ metabolites on the expression of osteogenesis-related factors in human periodontal ligament stromal cells (hPDLSCs) under inflammatory conditions. Inflammation was simulated by targeting Toll-like receptors (TLRs), which recognize specific components of pathogens and lead to induction of inflammatory responses.

Since the gene expression of osteogenesis-related factors does not always correlate with mineralization, it remained unclear whether inflammatory stimuli also affect the vitamin D₃-induced osteogenic differentiation. Therefore, the aim of the present study was to elucidate, if the 1,25(OH)₂D₃- and 25(OH)D₃-induced osteogenic differentiation of hPDLSCs is similarly affected by inflammatory conditions. In addition, the effects of inflammatory stimuli on the 1,25(OH)₂D₃- and 25(OH)D₃-triggered expression of osteogenesis-related factors were assessed in hPDLSCs incubated in osteogenic induction medium.

It was hypothesized that the 1,25(OH)₂D₃- and 25(OH)D₃-induced osteogenic differentiation of hPDLSCs and the expression of osteogenesis-related factors under osteogenic conditions are altered in the presence of inflammatory stimuli.

2 | MATERIALS AND METHODS

2.1 | Cell culture

Primary hPDLSCs were obtained from five periodontally healthy individuals undergoing third molar extraction due to orthodontic indications. The three female and two male donors were between 18 and 22 years old and had no chronic diseases or regular medication. Immediately after extraction, the teeth were gently washed with phosphate-buffered saline (PBS) and the periodontal ligament tissue adhering to the middle third of the root was scraped off using a scalpel. The tissue fragments were incubated in Petri dishes containing Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich, St. Louis, USA) supplemented with 1% penicillin/streptomycin (P/S; Gibco, Carlsbad, USA) and 10% foetal bovine serum (FBS; Gibco, Carlsbad, USA) under humidified conditions at 5% CO₂ and 37°C. After outgrowth of the hPDLSCs, they were transferred into cell culture flasks. Mesenchymal stromal cell character was assessed by flow cytometry analysis of characteristic mesenchymal surface markers CD29, CD31, CD34 and CD45. Notably, the isolated cell population is heterogeneous and might additionally contain osteoblasts, fibroblasts and odontoblasts, which express similar surface markers as MSCs. However, the isolated cells still meet the minimal criteria of mesenchymal stromal cells as defined by the position papers of the International Society for Cellular Therapy. Each of the subsequent experiments was conducted with hPDLSCs of five different donors within passage 4-6.

2.2 | Treatment protocol

hPDLSCs were seeded in 24 well plates at a density of 5 x 10⁴ cells/well together with 0.5 ml DMEM supplemented with 1% P/S and 10% FBS for 24 hours. For the following stimulation, osteogenic induction medium was prepared, which was...
composed of Minimum Essential Medium Eagle with alpha modification (α-MEM; Sigma-Aldrich, St. Louis, USA) supplemented with 20% FBS, 100 nM dexamethasone, 10 nM β-glycerophosphate and 0.05 nM ascorbic acid. After washing the hPDLSCs with PBS, cells were stimulated with osteogenic induction medium containing 1,25(OH)_{2}D_{3} (0-10 nM; Cayman Chemical, Ann Arbor, USA) or 25(OH)D_{3} (0-100 nM; Cayman Chemical, Ann Arbor, USA) in the presence and absence of either TLR4 and TLR2 agonist standard *P. gingivalis* LPS (1 µg/ml; Invivogen, San Diego, USA) or Pam3CSK4, which activates TLR2-TLR1 heterodimer (1 µg/ml; Invivogen, San Diego, USA). Since hPDLSCs lack of membrane-bound CD14, LPS treatment was performed in the presence of soluble CD14 (0.25 µg/ml; Sigma-Aldrich, St. Louis, USA) as reported previously, in order to enhance the LPS-induced response. hPDLSCs incubated only with osteogenic induction medium served as control group. Every 72 hours, 0.25 ml of the stimulation media were replaced by freshly prepared ones. The total treatment was conducted for 7, 14 and 21 days. Each experiment was performed in duplicates for every donor.

### 2.3 | Gene expression analysis

Quantitative polymerase chain reaction (qPCR) was performed in order to analyse the gene expression levels of osteogenesis-related factors osteocalcin (BGLAP), osteopontin (SPP1) and runt-related transcription factor 2 (RUNX2) in hPDLSCs treated for 7, 14 and 21 days. Cell lysis, mRNA extraction, transcription into cDNA and qPCR were executed with the TaqMan Gene Expression Cells-to-CT kit (Applied Biosystems, Foster City, USA), The Primus 96 advanced thermocycler (PeqLab/VWR, Darmstadt, Germany) was utilized to carry out reverse transcription. qPCR was performed with ABI StepOnePlus (Applied Biosystems, Foster City, USA) using following TaqMan Gene Expression Assays: BGLAP, Hs01587814_g1; SPP1, Hs00959010_m1; RUNX2, Hs00231692_m1. The analysis was conducted in duplicates at 95°C for 10 minutes, 40 cycles, each for 15 seconds at 95°C and at 60°C for 1 minute. Quantification of the gene expression levels was executed with the $2^{-\Delta\Delta Ct}$ method applying following formula:

$$
\Delta\Delta Ct = (c_{target}^{t} - c_{GAPDH}^{t})_{sample} - (c_{target}^{t} - c_{GAPDH}^{t})_{control}
$$

**Figure 1** 1,25(OH)_{2}D_{3}-induced gene expression levels of osteocalcin under inflammatory and osteogenic conditions. Primary hPDLSCs (n = 5) were stimulated with osteogenic induction medium containing 1,25(OH)_{2}D_{3} (0, 0.1, 10 nM) in the presence and absence of *P. gingivalis* LPS (1 µg/ml) or Pam3CSK4 (1 µg/ml) for 7 (A), 14 (B) or 21 (C) days. Resulting gene expression levels of osteocalcin were analysed with qPCR. Y-axes represent the n-fold expression of the target gene in relation with untreated hPDLSCs. Data are presented as mean ± standard error of the mean of five independent experiments. *Significant difference between groups, p < 0.05; # Significant decrease compared with respective vitamin D_{3} concentration in the absence of inflammatory stimuli, p < 0.05
hPDLSCs treated with osteogenic medium alone were considered as control group and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as endogenous control.

2.4 | Alizarin Red S staining

The presence of calcified deposition was assessed in hPDLSCs treated for 21 days by staining with Alizarin Red S. In detail, hPDLSCs were incubated with 4% paraformaldehyde in PBS for 10 minutes. After washing with PBS, cells were stained with Alizarin Red S (1.34 mg/ml; Sigma-Aldrich, St. Louis, USA) dissolved in distilled water for 15 minutes. The stained hPDLSCs were washed with PBS and captured photographically, followed by quantification of the Alizarin Red S staining intensity. For this purpose, cells were incubated with 10% acetic acid for 30 minutes. Subsequently, supernatants were collected and incubated at 85°C for 15 minutes before putting them on ice. The cooled down samples were centrifuged at 13,400 g for 15 minutes and the supernatants were again collected and mixed with 10% ammonium hydroxide. Alizarin Red S staining solutions were prepared to serve as standard. The absorbance was read with a microplate reader at 405 nm.

2.5 | Statistical analyses

The statistical analyses were conducted with SPSS 24.0 (IBM). Data were analysed by Friedman test, followed by Wilcoxon test for pairwise comparison. All data are presented as mean ± SEM of five independent experiments with five different donors performed in triplicates.

3 | RESULTS

3.1 | 1,25(OH)\textsubscript{2}D\textsubscript{3}– induced osteocalcin expression in hPDLSCs under osteogenic conditions is diminished in the presence of Pam3CSK4

Gene expression of osteocalcin by hPDLSCs after culture in osteogenic induction medium containing 1,25(OH)\textsubscript{2}D\textsubscript{3} (0, 0.1, 10 nM) in

![Figure 2](image-url)

**Figure 2** 1,25(OH)\textsubscript{2}D\textsubscript{3}–induced gene expression levels of osteopontin under inflammatory and osteogenic conditions. Primary hPDLSCs (n = 5) were stimulated with osteogenic induction medium containing 1,25(OH)\textsubscript{2}D\textsubscript{3} (0, 0.1, 10 nM) in the presence and absence of *P. gingivalis* LPS (1 µg/ml) or Pam3CSK4 (1 µg/ml) for 7 (A), 14 (B) or 21 (C) days. Resulting gene expression levels of osteopontin were analysed with qPCR. Y-axes represent the n-fold expression of the target gene in relation to untreated hPDLSCs. Data are presented as mean ± standard error of the mean of five independent experiments. *Significant difference between groups, $p < 0.05$; # Significant decrease compared with respective vitamin D\textsubscript{3} concentration in the absence of inflammatory stimuli, $p < 0.05$.
the presence and absence of *P. gingivalis* LPS (1 µg/ml) or Pam3CSK4 (1 µg/ml) for 7 (A), 14 (B) and 21 (C) days is demonstrated in Figure 1. While 0.1 nM 1,25(OH)₂D₃ had no effect on the basal expression of osteocalcin under physiological conditions, it was significantly enhanced by the highest 1,25(OH)₂D₃ concentration after 7, 14 and 21 days.

In the presence of Pam3CSK4, the 10 nM 1,25(OH)₂D₃-triggered osteocalcin expression was significantly decreased compared with physiological conditions at all tested time points. Interestingly, after 14 days incubation, treatment with Pam3CSK4 also led to a significant decrease of the basal and 0.1 nM 1,25(OH)₂D₃-induced osteocalcin expression. Inflammatory conditions simulated with either *P. gingivalis* LPS similarly diminished the osteocalcin expression induced by 10 nM 1,25(OH)₂D₃ after 7 (P = 0.116), 14 (P = 0.063) and 21 (P = 0.398) days, however, without a statistical significance.

### 3.2 Osteopontin gene expression levels of hPDLSCs induced by 1,25(OH)₂D₃ under osteogenic conditions are partially decreased by Pam3CSK4 and *P. gingivalis* LPS

Figure 2 illustrates the gene expression levels of osteopontin in hPDLSCs cultured in osteogenic induction medium supplemented with 0.1 or 10 nM 1,25(OH)₂D₃ under physiological and inflammatory conditions simulated with either *P. gingivalis* LPS (1 µg/ml) or Pam3CSK4 (1 µg/ml). Treatment of hPDLSCs was performed for 7 (A), 14 (B) and 21 (C) days. Similarly to osteocalcin, the expression of osteopontin was significantly enhanced by 10 nM 1,25(OH)₂D₃ in the absence of inflammatory stimuli after all treatment periods. In addition, a significant increase of the osteopontin expression could be observed after treatment with 0.1 nM 1,25(OH)₂D₃ under physiological conditions for 7 days. The osteopontin expression induced by 10 nM 1,25(OH)₂D₃ was significantly diminished in the presence of *P. gingivalis* LPS after 7 and 14 days in comparison with physiological conditions. A similar tendency was observed after 21 days, but the differences were not statistically significant (P = 0.075). Pam3CSK4 had no significant effect on the 10 nM 1,25(OH)₂D₃-triggered osteopontin expression after 7 days (P = 0.113), but led to a significant decrease of the osteopontin gene expression levels after 14 and 21 days.

### 3.3 1,25(OH)₂D₃ has no effect on the gene expression levels of RUNX2 in hPDLSCs under osteogenic and inflammatory conditions

RUNX2 gene expression in hPDLSCs after 7 (A), 14 (B) and 21 (C) days culture with osteogenic induction medium containing 1,25(OH)₂D₃ (0, 0.1, 10 nM) in the presence and absence of 1 µg/ml *P. gingivalis* LPS or 1 µg/ml Pam3CSK4 is shown in Figure 3. Stimulation with different 1,25(OH)₂D₃ concentrations had no significant effect on the RUNX2 expression under both, physiological and inflammatory conditions.

### 3.4 Osteogenic differentiation of hPDLSCs induced by 1,25(OH)₂D₃ remains unaltered in the presence of inflammatory stimuli

Figure 4B shows the photometrical analysis of Alizarin Red S stained hPDLSCs after culture in osteogenic induction medium containing 1,25(OH)₂D₃ (0, 0.1, 10 nM) in the presence and absence of inflammatory stimuli *P. gingivalis* LPS (1 µg/ml) or Pam3CSK4 (1 µg/ml) for 21 days. Representative pictures of hPDLSCs (n = 1) stained with Alizarin Red S are illustrated in Figure 4A.

In the absence of inflammatory stimuli, treatment with the highest 1,25(OH)₂D₃ concentration resulted in a significant increase of calcium deposits. In contrast, the vitamin D₃ metabolite had no significant effect on the optical density of Alizarin Red S stained hPDLSCs under inflammatory conditions.

### 3.5 25(OH)D₃ has no impact on the osteogenic differentiation and expression of osteogenesis-related factors of hPDLSCs under osteogenic conditions

The gene expression levels of osteocalcin, osteopontin and RUNX2 in hPDLSCs cultured in osteogenic induction medium containing 25(OH)D₃ (0, 1, 100 nM) after 21 days was illustrated in Figure 5. Figure 5E demonstrates the photometrical analysis of Alizarin Red S stained hPDLSCs after treatment with osteogenic induction medium containing 25(OH)D₃ (0, 1, 100 nM) after 21 days and representative pictures are shown in Figure 5D.

25(OH)D₃ neither had an effect on the expression of osteogenesis-related factors after 7, 14 and 21 days, nor influenced the osteogenic differentiation of hPDLSCs. Therefore, experiments conducted under inflammatory conditions are not shown.

### 4 DISCUSSION

Apart from its fundamental role for bone metabolism, vitamin D₃ is also well known for its anti-inflammatory and immunomodulatory properties. Currently, it is also discussed to play a role in preventing COVID-19 infection, progression and severity. Vitamin D₃ deficiency is prevalent in a pandemic extent and is associated with numerous health issues, including different bone diseases and periodontitis. Despite its positive effect on periodontal tissues, supplementation of vitamin D₃ during periodontal therapy has never been shown to be beneficial so far. In an attempt to provide a possible explanation for this, our previous study investigated the effects of vitamin D₃ metabolites on hPDLSCs in the presence of inflammatory stimuli. hPDLSCs have been shown to be strongly affected...
by vitamin D$_3$ metabolites and are moreover able to locally convert 25(OH)D$_3$ to 1,25(OH)$_2$D$_3$.\textsuperscript{6,35,36} We observed that the transcriptional activity of VDR is diminished in hPDLSCs under inflammatory conditions.\textsuperscript{22} In particular, we could show that the 1,25(OH)$_2$D$_3$- and 25(OH)D$_3$- induced gene expression levels of osteocalcin and osteopontin were significantly decreased in the presence of \textit{P. gingivalis} LPS and Pam3CSK4.

The goal of the present study was to reveal if these inflammatory stimuli also affect the vitamin D$_3$- induced osteogenic differentiation of hPDLSCs. In addition, the effects of \textit{P. gingivalis} LPS and Pam3CSK4 on the 1,25(OH)$_2$D$_3$- and 25(OH)D$_3$- induced gene expression levels of osteogenesis-related factors osteocalcin, osteopontin and RUNX2 were evaluated in hPDLSCs under osteogenic conditions.

In order to achieve this aim, hPDLSCs of five healthy donors were incubated in osteogenic induction medium containing different concentrations of 1,25(OH)$_2$D$_3$ and 25(OH)D$_3$ in the presence and absence of \textit{P. gingivalis} LPS and Pam3CSK4. Gene expression analysis of osteogenesis-related factors was conducted after 7, 14 and 21 days of incubation, whereas osteogenic differentiation was assessed after 21 days only.

The addition of 1,25(OH)$_2$D$_3$ to the osteogenic induction medium significantly enhanced the osteogenic differentiation of hPDLSCs. These results are in accordance with the findings of Nebel et al and Ji et al, who assessed vitamin D$_3$-induced osteogenic differentiation via alkaline phosphatase activity and Alizarin red S staining.\textsuperscript{14,15} Interestingly, the presence of inflammatory stimuli did not affect the 1,25(OH)$_2$D$_3$-triggered osteogenic differentiation of hPDLSCs. Therefore, the attenuating effects of \textit{P. gingivalis} LPS and Pam3CSK4, which have been observed in our previous study, could not be confirmed at this level.\textsuperscript{22} However, our results are in accordance with the recently published study of Karlis et al, who showed that TLR2 and TLR4 activation has no effect on the osteogenic differentiation of gingival fibroblasts.\textsuperscript{37}

In order to rule out any impact of the osteogenic induction medium, the effect of inflammatory stimuli on the 1,25(OH)$_2$D$_3$-triggered expression of osteogenesis-related factors was assessed under osteogenic conditions. Similarly to the findings of our previous study, stimulation with 1,25(OH)$_2$D$_3$ significantly increased the osteocalcin and osteopontin levels, which was observed after all treatment periods. In the presence of Pam3CSK4, the 10 nM 1,25(OH)$_2$D$_3$-induced osteocalcin expression was significantly
decreased after 7, 14 and 21 days. In case of the osteopontin expression, such an effect was only observed after 14 and 21 days. In contrast to our previous study, *P. gingivalis* LPS did not affect the 1,25(OH)$_2$D$_3$-triggered osteocalcin expression in the presence of osteogenic induction medium. However, the 1,25(OH)$_2$D$_3$-induced osteopontin expression was significantly decreased by *P. gingivalis* LPS after 7 and 14 days.

A possible explanation for these results could be the artificial additives in the osteogenic induction medium, such as dexamethasone. This glucocorticoid increases the transcription of VDR, and thus leads to an enhanced effectiveness of 1,25(OH)$_2$D$_3$, which could distort the results. Moreover, dexamethasone has anti-inflammatory properties, which could be viewed as a certain limitation for this study. However, according to Sung-Mi et al, dexamethasone is crucial for the osteogenic differentiation of hPDLSCs and hence, its addition was inevitable.

In addition, there are also other additives that might have influenced the results of this study. The additive β-glycerophosphate has been shown to cause ectopic mineralization as long as alkaline phosphatase is present and FBS possesses considerable immunosuppressive properties and inhibits the expression of pro-inflammatory cytokines.

Since all of these factors might contribute to distortions of the results, future studies should consider their potential role when studying the effect of different biologically active substances in osteogenic conditions in vitro. Furthermore, our data suggest that the changes in the expression of osteogenesis-related genes are not necessarily associated with alterations in mineralization, which should be also considered by further studies.

Treatment with osteogenic medium containing 25(OH)D$_3$ in a concentration similar to physiological serum levels (100 nM) had no influence on the osteogenic differentiation of hPDLSCs. We used 25(OH)D$_3$ in our study, because this metabolite is the main form of vitamin D$_3$ in blood, and it can be locally converted into 1,25(OH)$_2$D$_3$ by hPDLSCs. Several studies showed that 25(OH)D3 activates VDR-mediated response in hPDLSCs. So far, only Lou and coworkers observed enhancing effects of 25(OH)D$_3$ on the osteogenic differentiation of commercially available MSCs. Our recent study showed that 25(OH)D$_3$ significantly enhances the expression of osteogenesis-related proteins in hPDLSCs, but these experiments were performed in FBS-free medium without any supplements. In contrast, in the present study we did not observe any effect of 25(OH)D$_3$ on the expression of osteogenesis-related genes in hPDLSCs cultured in osteogenic induction medium. Thus, it seems that the cellular effects of 25(OH)D$_3$ in hPDLSCs depend on the experimental conditions, but the exact nature of this dependency should be further investigated.

The gene expression levels of RUNX2 were not affected by treatment with osteogenic induction medium containing vitamin D$_3$...
metabolites, which is in accordance with previous studies conducted on osteoblastic cell lines representing different maturation stages.\(^{45}\) Interestingly, treatment of hPDLSCs with inflammatory stimuli also had no impact on the gene expression of RUNX2. Unlike our data, Uehara et al. and Xing et al. reported inhibitory effects of \(P.\) gingivalis LPS on RUNX2 expression in hPDLSCs and bone marrow-derived MSCs, respectively. One possible explanation of these discrepancies might be the differences in the LPS concentration, which was 10 times lower in our study.\(^{46,47}\) However, the concentration used in our study has been shown to significantly enhance the inflammatory response of hPDLSCs, which was comparable to other strong inflammatory stimuli such as TLR2/1 agonist Pam3CSK4 and TLR3 agonist Poly I:C.\(^{24,25,48}\) Therefore, other factors such as stimulation protocol, cell source, LPS source and experimental conditions should be considered when comparing our data with those of other studies.

This study is limited by its in vitro character, which does not allow direct translation into the clinical situation. Osteogenic differentiation in vitro is a rather artificial process, which is hardly reflected in the in vivo situation. Another limitation is the use of hPDLSCs from young and healthy donors. Considering this aspect, this study could be extended by including hPDLSCs of periodontitis patients and age-matched healthy individuals. Furthermore, since third molars experience less occlusal forces, other teeth could be utilized for cell isolation.

Summarizing the data of this study, we could show that the 1,25(OH)\(_2\)D\(_3\)-triggered osteogenic differentiation of hPDLSCs is not affected under inflammatory conditions. However, the effects of 1,25(OH)\(_2\)D\(_3\) seem to be, at least partially, diminished by inflammatory stimuli under osteogenic conditions. Further studies are required to reveal the influence of inflammation on the effectiveness of vitamin D\(_3\) metabolites.

ACKNOWLEDGEMENTS
This study was supported by the Austrian Science Fund (FWF; project P 29440 to Oleh Andrukhov) and the Medical-Scientific Fund of the Mayor of Vienna (project 19010 to Alice Blufstein). The authors acknowledged Ms. Phuong Quynh Nguyen for excellent technical assistance.

AUTHOR CONTRIBUTIONS
AB, CB, OA, conceived and designed the data; AB, BK, JG, acquired the data; AB, AM, XR, OA, analysed and interpreted the data; AB, OA, drafted the article; CB, BK, JG, AM, XR, critically revised and edited the study. All authors: approved the manuscript.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Oleh Andrukhov https://orcid.org/0000-0002-0485-2142
REFERENCES

1. Hossein-Nezhad A, Holick MF. Vitamin D for health: a global perspective. Mayo Clin Proc. 2013;88(7):720-755.

2. Wacker M, Holick MF. Sunlight and vitamin D: a global perspective for health. Dermatoendocrinol. 2013;5(1):51-108.

3. Basit S. Vitamin D in health and disease: a literature review. Br J Biomed Sci. 2013;70(4):161-172.

4. Anderson PH, May BK, Morris HA. Vitamin D metabolism: new concepts and clinical implications. Clin Biochem Rev. 2003;24(1):13-26.

5. Zehnder D, Bland R, Williams MC, et al. Extrarenal expression of 25-Hydroxyvitamin D3-1α-Hydroxylase. J Clin Endocrinol Metab. 2001;86(2):888-894.

6. Andrukhov O, Andrukhova O, Hulan U, Tang Y, Bantleon HP, Rausch-Fan X. Both 25-hydroxyvitamin-D3 and 1,25-dihydroxyvitamin-D3 reduces inflammatory response in human periodontal ligament cells. PLoS One. 2014;9(2):e90301.

7. Bikle DD. Extraskeletal actions of vitamin D. J Inflamm Res. 2014;7:69-87.

8. Holick MF. Medical progress: vitamin D deficiency. N Engl J Med. 2007;357(3):266-281.

9. Andrukhov O, Blufstein A, Behm C, Moritz A, Rausch-Fan X. Both 25-hydroxyvitamin-D3 and 1,25-dihydroxyvitamin-D3 reduces inflammatory response in human periodontal ligament cells. PLoS One. 2012;7(12):e52053.

10. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317.

11. Wada N, Gronthos S, Bartold PM. Immunomodulatory effects of stem cells. Periodontol 2000. 2010;53:198-216.

12. Jönsson D, Nebel D, Brattahl G, Nilsson BO. The human periodontal ligament cell: a fibroblast-like cell acting as an immune cell. J Periodontol Res. 2011;46(2):153-157.

13. Nebel D, Svensson D, Aroensius K, Larsson E, Jönsson D, Nilsson BO. 1α,25-dihydroxyvitamin D3 promotes osteogenic activity and downregulates proinflammatory cytokine expression in human periodontal ligament cells. J Periodontol Res. 2015;50(5):666-673.

14. Ji Y, Zhang P, Xing Y, et al. Effect of 1α, 25-dihydroxyvitamin D3 on the osteogenic differentiation of human periodontal ligament stem cells and the underlying regulatory mechanism. Int J Mol Med. 2019;43(1):167-176.

15. Laky M, Bertl K, Harrilan H, et al. Serum levels of 25-hydroxyvitamin D are associated with periodontal disease. Clin Oral Investig. 2017;21(5):1553-1558.

16. Khammissa RAG, Ballyraam R, Jadwat Y, Fourie J, Lemmer J, Feller L. Vitamin D deficiency as it relates to oral immunity and chronic periodontitis. Int J Dent. 2018;2018:7315797.

17. Antonoglou GN, Knuuttila M, Niemelä O, et al. Low serum level of 25-Hydroxyvitamin D3 and dental mesenchymal stromal cells. J Periodontol 2020. 2020;9(2):e0148173.

18. Andrukhov O, Andrukhova O, Hulan U, Tang Y, Bantleon HP, Rausch-Fan X. Both 25-hydroxyvitamin-D3 and 1,25-dihydroxyvitamin-D3 reduces inflammatory response in human periodontal ligament cells. PLoS One. 2014;9(2):e90301.

19. Wada N, Gronthos S, Bartold PM. Immunomodulatory effects of stem cells. Periodontol 2000. 2010;53:198-216.

20. Hassell TM. Tissues and cells of the periodontium. Periodontol 2000. 2000;1993(3):9-38.

21. Hajishengallis G. Periodontitis: from microbial immune subversion to systemic inflammation. Nat Rev Immunol. 2015;15(1):30-44.

22. Blufstein A, Behm C, Kubin B, et al. Transcriptional activity of vitamin D receptor in human periodontal ligament cells is diminished under inflammatory conditions. J Periodontol 2020. Online ahead of print.

23. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335-376.

24. Behm C, Blufstein A, Gahn J, et al. Soluble CD14 enhances the response of periodontal ligament stem cells to toll-like receptor 2 agonists. Mediators Inflamm. 2019;2019:8127301.

25. Andrukhov O, Andrukhova O, Özdemir B, et al. Soluble CD14 enhances the response of periodontal ligament stem cells to P. gingivalis lipopolysaccharide. PLoS One. 2016;11(8):e0160848.
45. Gutiérrez OM. Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: Updating the “trade-off” hypothesis. Clin J Am Soc Nephrol. 2010;5(9):1710-1716.

46. Uehara O, Abiko Y, Saitoh M, Miyakawa H, Nakazawa F. Lipopolysaccharide extracted from Porphyromonas gingivalis induces DNA hypermethylation of runt-related transcription factor 2 in human periodontal fibroblasts. J Microbiol Immunol Infect. 2014;47(3):176-181.

47. Xing Q, Ye Q, Fan M, Zhou Y, Xu Q, Sandham A. Porphyromonas gingivalis lipopolysaccharide inhibits the osteoblastic differentiation of preosteoblasts by activating notch1 signaling. J Cell Physiol. 2010;225(1):106-114.

48. Blufstein A, Behm C, Gahn J, et al. Synergistic effects triggered by simultaneous Toll-like receptor-2 and -3 activation in human periodontal ligament stem cells. J Periodontal. 2019;90(10):1190-1201.

How to cite this article: Blufstein A, Behm C, Kubin B, et al. Effect of vitamin D3 on the osteogenic differentiation of human periodontal ligament stromal cells under inflammatory conditions. J Periodont Res. 2021;56:579–588. https://doi.org/10.1111/jre.12858